Blog

Biointron’s Antibodies After Hours: From Algorithms to Antibodies was held at The Hangar in South San Francisco, on Friday, September 4, 2026. “Antibodies After Hours” is a networking reception series from Biointron held in biotech hubs across the United States, with events previously hosted in S

Discover how high-throughput wet-lab validation connects AI-designed antibody sequences to experimental data, enabling faster screening and model refinement.

Understand the hybridoma generation process for monoclonal antibody production, including immunisation, cell fusion, screening, and clone selection.

Artificial intelligence (AI) is changing how therapeutic antibodies are discovered and developed. Advances in machine learning, protein structure prediction, and generative AI have made it possible to design and evaluate large numbers of antibody sequences computationally, expanding the range of candidates researchers can explore.

Biointron announces limited-time RushData launch pricing for high-throughput antibody production, binding characterization, and experimental data generation for AI-driven antibody discovery.

Learn how direct antigen labeling improves single B cell antibody screening by reducing background, enabling precise binding readouts, and supporting multiplex assays.

August 2026 brought another mix of acquisitions, licensing agreements, strategic collaborations, and private financings across the antibody biotech sector. Antibody-drug conjugate technologies, such as bispecific ADCs and new payload technologies, were mentioned, while autoimmune and inflammatory di

Antibody discovery often begins with a highly diverse population of B cells, only a fraction of which may produce antibodies with the desired specificity or functional properties. Single-cell screening provides a way to examine these cells individually while maintaining a connection between an antibody phenotype and the cell that produced it.

As larger candidate panels move from computational design into the laboratory, antibody production and characterization workflows need to accommodate hundreds or thousands of molecules in parallel.

The idea of single-cell technology​ is to examine B cells individually. Droplet microfluidics extends this principle by placing individual cells into extremely small reaction compartments that can be generated and analyzed at high throughput.

Discover how microfluidics is revolutionizing single B cell antibody screening with high-throughput precision. Explore applications, advantages, and Biointron’s platform.

Biointron's RushData platform is designed around this range of data needs. Built on 1-day CHO expression, RushData combines high-throughput antibody production with binding and developability assays to generate structured experimental datasets in days. The platform can support more than 20,000 molecules per week, with Basic, Standard and Premium packages providing broad assay coverage.